Latest Breaking News On - James dentzer - Page 1 : comparemela.com

Curis (CRIS) Announces Additional Data from TakeAim Leukemia Study

Curis (CRIS) Announces Additional Data from TakeAim Leukemia Study
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Robert martellJames dentzerCuris incTakeaim leukemiaRecommended phaseChief scientific officer

Curis to Present at Upcoming Healthcare Conferences in April

LEXINGTON, Mass., April 4, 2024 /PRNewswire/ Curis, Inc. , a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James.

James dentzerCompany presentationCuris incPrnewswire curis incDrug administrationRoche groupChief executive officerAnnual needham virtual healthcare conferenceAim lymphomaAim leukemiaOrphan drug designation

Curis (CRIS) Announces Initial Combination Study Data from its TakeAim Lymphoma Study

Curis (CRIS) Announces Initial Combination Study Data from its TakeAim Lymphoma Study
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

James dentzerCuris incTakeaim lymphomaChief executive officerHodgkin lymphomaComplete responseNon hodgkin lymphoma

Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference

Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

James dentzerExchange commissionCuris incRoche groupDrug administrationTakeaim leukemia studyTakeaim leukemiaChief executive officerComplete responseAim leukemia studyAim lymphomaAim leukemiaOrphan drug designationNote regarding forward looking statementsSecurities litigation reform actOberland capital

Curis Inks Deal With Florida University For Emavusertib/Pembrolizumab Combination Study In Melanoma

(RTTNews) - Curis, Inc. (CRIS), Tuesday said it has reached a clinical trial agreement with the University of Florida to study the combination of .

James dentzerCuris incUniversity of floridaPatients with melanoma brain